Self-invented Intracavitary ECG Wire VS the Commercial System - Certodyn®
Sponsor:
Mahidol University
Collaborators:
Information provided by (Responsible Party):
Prasert Sawasdiwipachai，Mahidol University
| Tracking Information | |||
|---|---|---|---|
| First Submitted Date ICMJE | October 1, 2018 | ||
| First Posted Date ICMJE | October 5, 2018 | ||
| Last Update Posted Date | October 5, 2018 | ||
| Actual Study Start Date ICMJE | August 1, 2018 | ||
| Estimated Primary Completion Date | June 30, 2019 (Final data collection date for primary outcome measure) | ||
| Current Primary Outcome Measures ICMJE |
Signal noise ratio[ Time Frame: 10 min ] Measuring the segment of ECG noise (if exists) in millimeters compare to the total ECG segment. Compare this signal noise ration between the baseline surface ECG, the self-invented wire derived iECG and the Certodyn derived iECG. |
||
| Original Primary Outcome Measures ICMJE | Same as current | ||
| Current Secondary Outcome Measures ICMJE |
|
||
| Descriptive Information | |||
| Brief Title ICMJE | Self-invented Intracavitary ECG Wire VS the Commercial System - Certodyn® |
||
| Official Title ICMJE | Comparison of the Self-invented Intracavitary ECG Wire With the Commercial System - Certodyn® |
||
| Brief Summary | Peripherally Inserted Central Catheter (PICC) is considered a central venous line placement (CVL) which mandates the confirmation of the tip's location. At present, most CVL's position are confirmed by radiographic method either by in-procedure fluoroscopy or post-insertion x-ray. For CVLs placed from upper body (from internal jugular vein, subclavian veins or upper arm veins), the intracavitary electrocardiogram (iECG) can also be used. Intracavitary ECG are proven effective for tip confirmation and provide some benefits i.e. lower cost, decrease exposure to harmful radiation for care providers and also the patients, require less personals and equipments, provide real-time confirmation as comparable to fluoroscopy, etc. There are several devices and makes of iECG apparatus but B.Braun-Certodyn® remains the only available system in Thailand. The limitation is the availability of the Certodyn devices on each locations where CVL will be placed i.e. operating theater, intensive care unit, bedside placement, radiology suite, etc. Since the connecting wire is only supplied in the certain CVL kits under B.Braun brand, this has rendered iECG for other types or makes of CVL or PICC line become even more difficult. Self-invented connector wire for iECG (PS wire) has been made and used effectively in the past few years at Siriraj hospital. The patent registration is underway and the author seek to compare this PS wire against the commercial Certodyn system. |
||
| Detailed Description | Objective 1. To evaluate the success rate of iECG CVL tip confirmation by self-invented iECG connector wire. 2. To compare quality of iECG tracing produced from both of self-invented iECG wire versus the Certodyn system. Materials, participants and study method Equipments required: 1) Self-invented iECG wire (PS wire) 2) Commercial iECG system which consists of the Certodyn and the wire. 3) Standard ECG monitoring system which can display and printout the ECG tracing. 4) A digital ECG caliper which can measure P wave amplitude and noise segment in millimeter up to 2 decimal points. Study method 1. Patient presented for PICC line from upper torso will be screened and assessed for eligibility. 2. Exclusion criteria includes children younger than 18 yo, patient with atrial fibrillation or other rhythms not generated from intrinsic SA node i.e. pacer, unstable hemodynamic, patient with history arrhythmias, HR > 120 bpm, patients with hypercoagulable state, allergy to heparin or patients with known heparin induced thrombocytopenia, patients with known Creutzfeldt-Jakob Disease 3. Obtain informed consent. 4. Patient will be monitored with standard 3-lead ECG, the baseline lead II ECG will be printed out and tagged with a serial number. 5. Patient will undergo the standard PICC line placement using Seldinger or modified Seldinger technique. The catheter will be pre-flushed with 10 units/mL heparinized NSS. When Figure 1: A spreadsheet of 2 parameters measured in 10 pilot cases Figure 2: A captured screen of nQuery for calculation of sample size, the first 2 columns were calculated from the P wave amplitude and the last 2 columns were from the noise segment catheter is inserted into the proximal SVC (guided by landmark measurement), the wire will be retracted to the marked location where the tip of the wire is at the end of the catheter. The iECG connection by Certodyn will be applied. The catheter and wire will be adjusted until the giant P wave (highest P) was detected on screen, this ECG tracing will be printed out and tagged with another non-sequential serial number. The iECG will then switched to the PS wire and the iECG tracing will be printed out again and tagged with another non-sequential serial number. All 3 ECG printouts will be stapled together for measurement by cardiologist who is blind to the intervention later. 6. The intervention related to research study is considered ended at this point. The patient will have their CVL/PICC line adjusted to the proper position (mid to distal SVC for mid-long term and long term catheter). The CVL or PICC will be secured, flushed and locked per standard protocol. 7. Portable CXR will be routinely obtained when patients arrived to the ward. The information of the tip of the catheter will be recorded as well. Data analysis 1. Demographic data, type of catheter, depth of catheter where giant P wave obtained and final position of catheter will be recorded. 2. Each study patient produce 3 ECG print outs which are -baseline surface lead II ECG - iECG produced by Certodyn system - iECG produced by PS wire Each ECG tracing will be evaluated and measured by a cardiologist who is blind to the intervention. The 2 measured parameters includes: - The amplitude of P wave in mm from baseline surface ECG of each cardiac cycle. -The amplitude of giant P wave in mm from iECG from both Certodyn and PS wire. 3. All 3 ECG print outs will be compared for quality and the length noisy ECG segment (determined as the ECG with interference artifact of baseline > 1 mm) will also be measured in mm. 6) All measurement will be analyzed statistically to determine the differences between the 2 systems. | ||
| Study Type ICMJE | Interventional | ||
| Study Phase | N/A | ||
| Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Crossover Assignment Intervention Model Description: Single center, prospective, cross over study Masking: Interventional Masking Description:unlabeled ECG print Primary Purpose: Diagnostic |
||
| Condition ICMJE | |||
| Intervention ICMJE |
|
||
| Study Arms |
|
||
| Recruitment Information | |||
| Recruitment Status ICMJE | Recruiting | ||
| Estimated Enrollment ICMJE |
36 | ||
| Original Estimated Enrollment ICMJE | Same as current | ||
| Estimated Study Completion Date | October 31, 2019 | ||
| Estimated Primary Completion Date | June 30, 2019 (Final data collection date for primary outcome measure) | ||
| Eligibility Criteria ICMJE | Inclusion Criteria: - Patient age 18 years and above. - Requires PICC line insertion from upper torso. Exclusion Criteria: - Children younger than 18 years. - Patient with atrial fibrillation or other rhythms not generated from intrinsic SA node i.e. pacer, atrial fibrillation, etc. - Unstable hemodynamic. - Patient with history arrhythmias. - Patient with HR > 120 bpm. - Patients with hypercoagulable state. - Allergy to heparin. - Patients with known heparin induced thrombocytopenia. - Patients with known Creutzfeldt-Jakob Disease. | ||
| Sex/Gender |
|
||
| Ages | 18 Years and older (Adult, Older Adult) | ||
| Accepts Healthy Volunteers | No | ||
| Listed Location Countries ICMJE | Thailand | ||
| Removed Location Countries | |||
| Administrative Information | Has Data Monitoring Committee | No | |
| U.S. FDA-regulated Product |
Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No |
||
| IPD Sharing Statement |
|
||
| Responsible Party | Prasert Sawasdiwipachai，Mahidol University | ||
| Study Sponsor ICMJE | Mahidol University | ||
| Collaborators ICMJE | |||
| Investigators ICMJE |
|
||
| PRS Account | Mahidol University | ||
| Verification Date | October 2018 | ||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||
请使用微信扫码报名
京公网安备 11010102003638号